NOVATO, Calif., July 5, 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced that Patrice P. Rioux, M.D., Ph.D., Chief Medical Officer of Raptor, will present an overview of the Company at the Seventh Annual JMP Securities Healthcare Conference in New York, NY at The Peninsula New York. Raptor's Presentation will take place on Thursday, July 12, 2012 beginning at 11:30 a.m. ET.

A live audio webcast and 14-day archive of the JMP presentation will be available at http://ir.raptorpharma.com/events.cfm

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ("Raptor") seeks to research, produce, and deliver medicines that improve life for patients with severe, rare disorders. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, Non-alcoholic Steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase deficiency ("ALDH2"), and thrombotic disorder.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins that are designed to target cancer and infectious diseases.

For additional information, please visit www.raptorpharma.com.

The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180

CONTACT: Trout Group (investors)
         Lauren Glaser
         (646) 378-2972
         lglaser@troutgroup.com
         
         EVC Group (media)
         Janine McCargo
         (646) 688-0425
         jmccargo@evcgroup.com